← Back to Search

Antihistamine

Treatment for Anticholinergic Syndrome

Phase 4
Waitlist Available
Led By Michelle Rainka, PharmD
Research Sponsored by Dent Neuroscience Research Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Medically-stable volunteers of either gender between 35 and 50 years old or over the age of 65
No medication changes anticipated for the duration of the study except as defined in protocol
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after diphenhydramine administration (30, 60, 210, 240, 450, 480 minutes after diphenhydramine administration)
Awards & highlights

Study Summary

This trial will look at how much and for how long the brain is affected by a single dose of the drug diphenhydramine when given through an IV.

Eligible Conditions
  • Anticholinergic Syndrome
  • Pharmacokinetics of Diphenhydramine

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before and after diphenhydramine administration (30, 60, 210, 240, 450, 480 minutes after diphenhydramine administration)
This trial's timeline: 3 weeks for screening, Varies for treatment, and before and after diphenhydramine administration (30, 60, 210, 240, 450, 480 minutes after diphenhydramine administration) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in score of battery of cognitive function tests
Secondary outcome measures
Elderly vs. adult change in score of battery of cognitive function tests after diphenhydramine
Elderly vs. adult diphenhydramine AUC
Elderly vs. adult score of battery of cognitive function tests at specified time points

Find a Location

Who is running the clinical trial?

Dent Neuroscience Research CenterLead Sponsor
5 Previous Clinical Trials
111 Total Patients Enrolled
Michelle Rainka, PharmDPrincipal InvestigatorDent Neurologic Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Mar 2025